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Both sporadic and familial Alzheimer’s disease (AD) patients exhibit increased chromosome aneuploidy, particularly trisomy
21, in neurons and other cells. Significantly, trisomy 21/Down syndrome patients develop early onset AD pathology. We
investigated the mechanism underlying mosaic chromosome aneuploidy in AD and report that FAD mutations in the
Alzheimer Amyloid Precursor Protein gene, APP, induce chromosome mis-segregation and aneuploidy in transgenic mice and
in transfected cells. Furthermore, adding synthetic A peptide, the pathogenic product of APP, to cultured cells causes rapid
and robust chromosome mis-segregation leading to aneuploid, including trisomy 21, daughters, which is prevented by LiCl
addition or Ca2 chelation and is replicated in tau KO cells, implicating GSK-3, calpain, and Tau-dependent microtubule
transport in the aneugenic activity of A. Furthermore, APP KO cells are resistant to the aneugenic activity of A, as they have
been shown previously to be resistant to A-induced tau phosphorylation and cell toxicity. These results indicate that
A-induced microtubule dysfunction leads to aneuploid neurons and may thereby contribute to the pathogenesis of AD.
INTRODUCTION
Developing early diagnoses and successful treatments for Alz-
heimer’s disease (AD) will be greatly aided by a clear under-
standing of all steps in the pathogenic pathway that leads to
amyloid deposition, neurofibrillary tangle formation, inflam-
mation, and neurodegeneration in the brain. Although most
AD is “sporadic,” a large proportion is at least partly “familial”
in that patients develop the disease by inheriting a mutant gene
or a risk-enhancing genetic polymorphism. Autosomal domi-
nant mutations, accounting for 5% of AD, have been de-
scribed in three genes, and their analysis has provided espe-
cially important insights into the AD pathogenic pathway
(Glenner and Wong, 1984; Hardy and Selkoe, 2002). One of
these genes encodes the amyloid precursor protein (APP) from
which the key amyloid component, the A peptide, is derived
by proteolysis. Although mutations in the APP gene itself
account for1% of AD, they provided the proof that APP and
A are central to the disease process.
Most autosomal dominantly inherited familial Alzhei-
mer’s disease (FAD) is caused by mutations in two preseni-
lin genes, most commonly PS-1. The PS proteins must there-
fore also occupy a key place in the AD pathogenic pathway
together with APP and the A peptide. The role of the
presenilins in AD pathology was clarified when they were
found to form the enzymatic core of the -secretase complex
that cleaves APP in its transmembrane region and generates
the C-terminus of the A peptide (Wolfe, 2003).
Several lines of evidence indicate that both sporadic and
familiar AD patients, including those carrying APP and PS
mutations, are abnormal in one or more aspects of the cell cycle
(for reviews, see Obrenovich et al., 2003; Potter, 2004, 2008). For
example, Down syndrome (DS) patients, who carry three cop-
ies of chromosome 21 in all of their cells due to meiotic chro-
mosome mis-segregation in one of (usually) their mother’s
germ cells, invariably develop AD-like pathology by the age
30–40 (Olson and Shaw, 1969; Glenner and Wong 1984; Ep-
stein, 1990). This and other findings led us to propose that over
a lifetime, defective mitoses lead to the accumulation of aneu-
ploid cells throughout the body, including the brain. When
such chromosome mis-segregation generates trisomy 21 cells,
the extra copy of the APP gene on chromosome 21 contributes
to the development of Alzheimer neuropathology and demen-
tia (Potter, 1991). The microtubule (MT) disfunction likely re-
sponsible for the aneuploidy in AD patients could also affect
other aspects of cell physiology, especially in neurons.
The chromosome mis-segregation/MT disfunction hy-
pothesis of AD makes several easily-testable predictions
(Potter, 1991). For example, AD patients should be mosaic
for trisomy 21, and, indeed, we found trisomy 21 and other
aneuploid cells in primary skin fibroblast cultures from pa-
tients with both the familial (early age of onset) and sporadic
(late age of onset) forms of the disease (Potter et al., 1995;
Geller and Potter, 1999). Trisomy 21 cells have also been
observed among peripheral blood lymphocytes, buccal cells,
and brain neurons from sporadic AD patients and among
lymphocytes of mothers who, at a young age, gave birth to
a DS child and are prone themselves to develop AD later in
life (Schupf et al., 1994; Migliore et al., 1999, 2006; Yang et al.,
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2001; Mosch et al., 2007; Thomas and Fenech, 2008; Iourov et
al., 2009). Conversely, between 1 and 10% trisomy 21 mosa-
icism has also been found in individuals with otherwise
unexplained AD-like dementia in middle age, indicating
that even small numbers of trisomy 21 cells can lead to
cognitive deficits (Rowe et al., 1989; Shapiro et al., 1989; Puri
et al., 1994; Ringman et al., 2008).
Advanced AD patients also develop tetraploid neurons
(Yang et al., 2001; Mosch et al., 2007), which may indicate
entry into an incomplete cell cycle (Vincent et al., 1996;
Obrenovich et al., 2003; Varvel et al., 2008). Through the
elegant use of several techniques, Arendt and colleagues
found increases in both aneuploid and tetraploid neurons in
AD brain, with the 30% aneuploid cells (between 2n and
4n) being 10 times more common than tetraploid neurons
(Mosch et al., 2007).
Another prediction of the chromosome mis-segrega-
tion/MT disfunction hypothesis for AD is that the very
genes that, when mutant, cause familial AD should encode
proteins that are involved in the cell cycle and chromosome
segregation. Indeed, a polymorphism in the PS-1 gene is
associated with both an increased risk of developing AD and
of having a Down syndrome child (Wragg et al., 1996; Higu-
chi et al., 1996; Petersen et al., 2000; Lucarelli et al., 2004).
Furthermore, immunocytochemical and FRET results have
shown that endogenous PS-1 and APP and some of their
interacting proteins reside in cell structures involved in mi-
tosis, such as the nuclear membrane, centrosomes, or kinet-
ochores (Zimmermann et al., 1988; Li et al., 1997; Honda et al.,
2000; Johnsingh et al., 2000; Kimura et al., 2001; Tezapsidis et
al., 2003; Zitnik et al., 2006; Nizzari et al., 2007) and become
hyperphosphorylated during mitosis (Pope et al., 1994;
Suzuki et al., 1994; Preuss et al., 1995).
Previously, we used transgenic and knockin mice and
transfected cells in culture to test directly the effect of the
PS-1 gene on the cell cycle. All assays, tissues, and cells
yielded the same results and allowed the conclusion that
overexpression or mutation of PS-1 leads to chromosome mis-
segregation and aneuploidy, including trisomy 21 (Boeras et
al., 2008; Potter, 2008). Analysis of the PS-1–transfected cells
by immunocytochemistry revealed numerous abnormalities
in the mitotic spindle apparatii, including improper MT
arrays and lagging chromosomes. Finally, dominant nega-
tive mutant forms of presenilin failed to induce chromosome
mis-segregation, showing that presenilin/-secretase is di-
rectly involved in the mutant PS-1–induced cell cycle and
chromosome segregation defects.
During the course of these studies, we noted that the
percentage of cells with abnormal chromosome comple-
ments that arose in the PS-1–transfected cultures was often
higher than the measured transfection efficiency. This fact
strongly suggested that the PS-1 effect on chromosome mis-
segregation was not restricted to the PS-1–expressing cells,
but also extended to adjacent, nontransfected cells (i.e., was
non-cell autonomous) and thus might be induced by a se-
creted molecule. Coupling this observation to the fact that
-secretase activity was essential for the PS-1–induced chro-
mosome mis-segregation and to the previous finding that
patients carrying FAD mutations in APP also developed
trisomy 21 mosaicism led us to hypothesize that secreted A
peptide itself might induce cell cycle defects including chro-
mosome mis-segregation (Boeras et al., 2008).
In this article we test whether 1) expression of an FAD
mutant APP gene in transgenic mice or in transfected cells
leads to chromosome mis-segregation, particularly in brain
neurons, 2) exposing cells in culture to A peptide itself
leads to chromosome mis-segregation, 3) Ca2 chelation or
exposure to LiCl (two treatments that have been shown to
obviate A toxicity by inhibition of calpain and GSK-3,
respectively) prevent A from inducing chromosome mis-
segregation, and finally whether 4) knocking out the MT
associated protein Tau involved in both mitosis and AD also
causes chromosome mis-segregation.
MATERIALS AND METHODS
Mice
Transgenic mice expressing human APP with the V717F APP mutation (19–21
months) or knocked out for APP (3 months) and their nontransgenic litter-
mates were used. Tau/ mice and Tau/ mice and their nontransgenic
Tau/ controls were 6–7 mo old (Jackson Labs). All mice used in this study
had C57BL/6 background strain.
Primary Cells
Mouse primary splenocytes were prepared for metaphase chromosome anal-
ysis and fluorescence in situ hybridization (FISH; Boeras et al., 2008). Mouse
brains were harvested, the meninges and cerebella were removed, and cells were
obtained by triturating brain pieces in ice-cold 1 PBS (Cellgro, Manassas, VA)
40 times with fire-polished Pasteur pipettes of different pore sizes. The cell
suspension was fixed in cold 3:1 anhydrous methanol:acetic acid fixative and
kept on ice for at least 30 min. Fixed brain cells were stored at20°C before any
downstream assay was performed.
Cell Line
The hTERT-HME1 cell line is a primary human mammary epithelial cell line that
permanently expresses the telomerase reverse transcriptase (Clontech, Palo Alto,
CA) and has a stable karyotype (Jiang et al., 1999). Cells were maintained in
supplemented mammary epithelium basal medium (MEBM, Lonza, Hopkinton,
MA) and passaged every 2–3 d according to the supplier’s recommendations. All
experiments were conducted with the hTERT cells passages 3–6.
Plasmids
Plasmids constructed by inserting an FAD combination mutant NL-APP
K595N/M596L (Swedish) and V642I (London) APP gene cDNA into the
pcDNA3.1 expression vector or FAD mutant V717I into pAG3 vector were
gifts of Dr. Chad Dickey (University of South Florida, Tampa) and Todd
Golde (Mayo Clinic, Jacksonville). NucleoBond Plasmid Purification kit (BD
Biosciences, San Diego, CA) was used for nucleic acid purification.
Transient Transfections
One day before the transfection, the hTERT cells (1–1.5 105 cells/2 ml) were
plated in a six-well plate and grown in supplemented MEBM. A FuGene6
(Roche Applied Science, Indianapolis, IN)-DNA complex was prepared ac-
cording to the manufacturer’s recommendations using a ratio of Fugene 6 to
DNA of 3 L:1 g and was applied to the cells. At 48 h after transfection, cells
were either harvested immediately for FISH or treated with 37 ng/ml colce-
mid for 6–7 h before the harvest, collected, fixed, and scored for aneuploidy
in metaphase chromosome spreads.
Peptides and Salts
Synthetic A1-40, A1-42, and A42-1 from either BioSource International
(Camarillo, CA) or American Peptide Company (Sunnyvale, CA) were resus-
pended in sterile HPLC water at room temperature, aliquoted, and stored at
80°C before use. Other control peptides were custom made by either Sigma
Genosys (St. Louis, MO) or Bio-Synthesis (Lewisville, TX), and were designed by
random scrambling of the A12-28 or A1-42 sequence (NH2-VHHQKLVF-
FAEDVGSNK-OH and NH2-ADFVGSVINIGKLELKMVGQVGVHGIAE-
VHFDYSFADHEARG-OH), respectively. Similarly, LiCl (Fisher Scientific, Pitts-
burgh, PA) and BAPTA (Invitrogen, Carlsbad, CA) salts were resuspended in
HPLC water.
In Vitro Incubation of the Primary Cells and Cell Lines
with A Peptides, BAPTA, and LiCl
For each experiment, a fresh aliquot of the various A peptides, BAPTA, or LiCl
was used and thawed on ice to avoid repeated thaw-freeze cycles and possible
changes in the structure of the molecules. Primary mouse splenocytes were
stimulated to divide in concanavalin A (Con-A) containing media for 44 h in
either 100-mm dishes (7.5–8 105 cells/10 ml growth media) or in six-well plates
(4–5 105 cells/3 ml growth media). The cells were treated with A peptide for
44–48 h and prepared according to established cytogenetic procedures described
below. In coincubation experiments, the Tau/ splenocytes were pretreated
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with either 1 M of BAPTA for 3 min before the peptides were added or with 2.5
mM of LiCl for the last 7 h of A peptide incubation.
Similarly, 24 h before A treatment, a low passage of the hTERT-HME1
cells was seeded in either six-well dish (1–1.5 105 cells/well) or in a 100-mm
culture dish (4–5 105 cells/55 cm2). For the last 10–12 h of peptide exposure,
the cells were treated with 33 ng/ml colcemid, harvested, fixed, and scored
for aneuploidy by either karyotype analysis or FISH.
Metaphase Chromosome Analysis
After colcemid treatment, cells were harvested according to standard
cytogenetic methods as described (Boeras et al., 2008). Genus 2.81 software
(Applied Imaging, San Jose, CA) and the Metafer 3.31 Slide Scanning System
(MetaSystems, Altslussheim, Germany) with Isis 5.2 (ver. 2007; MetaSystems)
was used for metaphase spreads capture and chromosome analysis. At least
80 mouse splenocyte metaphases and 45 hTERT-HME1 cells metaphase
spreads were analyzed per each sample.
FISH
A bacterial artificial chromosome (BAC) containing a mouse chromosome
16 –specific sequence (a gift from Dr. Bruce Lamb at Case Western Reserve
University) was labeled by nick translation (Abbot, Vysis, Downer’s
Grove, IL) as described elsewhere (Kulnane et al., 2002; Boeras et al., 2008)
with modification. Specifically, 1 mM of either Spectrum Green dUTP
(Abbot, Vysis) or Spectrum Orange dUTP (Enzo Life Science, Bedford,
MA) was used to label 1 g of BAC DNA. The preincubated (37°C over
night) BAC probe was used for FISH of mouse primary cells. Labeled BAC
probe and mouse brain cells dehydrated in ethanol solutions (70, 80, and
90%) were codenatured at 74°C for 4 min and hybridized at 37°C for 22 h
in the HyBrite (Vysis) hybridization chamber followed by additional 20 –22
h of hybridization at 38°C. Excess probe was removed by three consecutive
washes in 0.4 SSC at 37°C for 4 min, 2 SSC/0.1% NP40 at room
temperature for 3 min, and 4 SSC/0.1% NP40 for 2 min. DAPI II (Abbot,
Vysis) or Vectashield (Vector Laboratories, Burlingame, CA) counterstain
was used to stain nuclear DNA. Mouse spleen cells were subject to similar
in situ protocol except they required shorter hybridization time and less
thorough washing.
Interphase FISH of hTERT-HME1 cells was performed using the LSI TEL/
AML1 ES Dual Color Translocation Probe (Abbot, Vysis). Hybridizations
were done according to Vysis recommendations for LSI probes in the HyBrite
hybridization chamber (Vysis) and counterstained with DAPI II.
Image Acquisition and Analysis
Hybridization signals were scored according to Vysis guidelines using
either a Nikon Eclipse E1000 microscope (Melville, NY) with a 4912 CCIR
high-performance Cohu CCD camera (San Diego, CA) and Genus 2.81
software for image processing (Applied Imaging, San Jose, CA) or a Zeiss
Imager.M1 Axio microscope with a CV-M4CL high-resolution camera
(Thornwood, NY). In interphase cells, only bright and compact signals
were counted separately for each probe using DAPI, FITC, and TRITC
Nikon filter cubes with a Nikon Eclipse E1000 fluorescence microscope and
Genus 2.81 software or under 49 DAPI, 38 HE Green Fluorescent, and
43HE Red Zeiss filters with a Zeiss Imager.M1 Axio fluorescence micro-
scope. The Abbott/Vysis (http://www.abbottmolecular.com/DualColor
Enumeration_36752.aspx) guidelines were followed meticulously. Partic-
ularly important is that, as required, closely adjacent double spots, double
spots linked by a light fluorescent thread, and defused signals were
counted as only single spots (i.e., one chromosome) and not two spots (i.e.,
two chromosomes).
Antibodies
For immunocytochemistry and immunofluorescence we used anti--tubulin
(Sigma, clone B-5-1-2), 1:500; Ms X Neuronal Nuclei (NeuN) AlexaFluor 488
(Millipore, Bedford, MA), 1:100; and Alexa Flour 488 rabbit -mouse IgG
(Invitrogen, Molecular Probes, Eugene, OR), 1:1000.
Immunocytochemistry after FISH
Immediately after hybridization, brain cells were incubated in 1 PBS for 10
min. The slides were blocked in 10% goat serum/0.1% Triton X-100 1 PBS
solution for 1 h. Conjugated Ms X Neuronal Nuclei AlexaFluor 488 (Millipore)
was diluted 1:100 in 1% BSA/0.1% Triton X-100 1 PBS and applied to the
slides overnight to stain for neurons. After final washes, coverslips were
mounted onto slides with DAPI II (Abbot, Vysis).
Statistical Analysis
Paired Student’s t test was used to compare the aneuploidy induced by
different peptide and inhibitor treatments and plasmid transfections in mul-
tiple experiments and to compare the levels of aneuploidy in mouse primary
cell line with and without a human FAD transgene. At least 10–12 mice were
analyzed for each graph and five to seven transfections/treatments of each
plasmid/peptide were scored for aneuploidy.
RESULTS
Expression of FAD Mutant APP Causes Chromosome
Mis-Segregation in Transgenic Mice
To understand the mechanism by which chromosome aneu-
ploidy arises in AD, we asked whether the expression of
FAD-mutant APP disrupts the cell cycle and causes chro-
mosome mis-segregation. First, metaphase chromosome
analysis was used to compare the chromosome complement
of FAD-APP–expressing transgenic mice (PDAPP) and age-
matched normal mice. Primary splenocytes were chosen for
this analysis because they can be induced to divide in cul-
ture, a requirement for metaphase analysis, and the trans-
gene promoter is active in the spleen. The dividing cells
were arrested at metaphase by colcemid treatment and the
chromosomes stained and counted. The data showed twice
the level of aneuploidy (i.e., 25% of cells with both less or
more than the normal mouse complement of 40 chromo-
somes) in the FAD-APP animals compared with nontrans-
genic animals (Figure 1A). There was no increase in the
number of tetraploid/polyploid cells (not shown).
FISH allows aneuploidy for particular chromosomes to be
assessed at all phases of the cell cycle. A BAC carrying a
300-kb fragment of mouse chromosome 16 (Kulnane et al.,
2002) was labeled with spectrum green dUTP (Abbott) by
nick translation and used as a hybridization probe to tag
chromosome 16 in transgenic and normal mouse spleno-
cytes (Figure 1B). Expression of the mutant APP transgene
induced a many-fold increase in both trisomy and mono-
somy 16 (Figure 1, C and D).
Figure 1. Chromosome aneuploidy induced in transgenic mouse
splenocytes carrying an AD mutant APP transgene (V717F). (A)
Karyotype analysis of nontransgenic (NON) and transgenic
APP/ mice showed significantly higher levels of aneuploidy
in the cells harboring a mutant APP transgene, but no increase in
tetraploidy/polyploidy. In situ DNA FISH with a BAC plasmid
containing mouse chromosome 16 (B) showed significantly
higher levels of trisomy 16 (C) and monosomy 16 (D) in APP/
splenocytes compared with cells from NON transgenic controls.
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Chromosome Aneuploidy in Neurons from FAD-APP
Transgenic Mice
The effect of an FAD mutation (V717F) in the APP gene on
the chromosome complement of brain cells was examined
using DNA FISH, which can be used to count chromo-
somes in both the nondividing neurons and cycling cells
such as glia. Whole brains from PS-1 transgenic and non-
transgenic mice were processed to yield suspensions of
mixed primary cells. The cells were fixed to slides and
hybridized with the mouse chromosome 16 BAC probe
labeled with Orange-dUTP. The hybridization efficiency
was 90%, with most cells being disomic, i.e., exhibiting
two signals (Figure 2A). By colabeling with Neu-N anti-
body, we found that 6.5% of neurons in APP transgenic
mice were trisomic for chromosome 16 compared with
1.5% of neurons in nontrangenic mice brain (Figure 2B).
There was no increase in aneuploidy in nonneuronal cells
(Neu-N negative; Figure 2C). These robust results with
one chromosome probe indicate that even more tgAPP
neurons are likely to be aneuploid, just as 5% trisomy 16
among spleen cells correlated to 25% total aneuploidy in
metaphase spreads (which cannot be generated for post-
mitotic neurons).
Small numbers of tetraploid neurons have been reported
in AD humans and mice and interpreted as being due to
adult neurons reentering the cell cycle and completing DNA
replication, but failing to complete cell division (Yang et al.,
2001, 2006; Obrenovich et al., 2003; Mosch et al., 2007; Zhu et
al., 2008). We observed no increase in tetrasomy 16 in dis-
aggregated cells from APP mice brains compared with non-
transgenic brains (Figure 2D); see also Iourov et al. (2009),
who also report finding human AD cortical neurons with
trisomy 21 but very few neuronal or nonneuronal cells
showing tetrasomy or polyploidy.
These and previous results show that expression of FAD
mutant forms of either APP or PS-1 in transgenic mouse
models of AD disrupts normal mitosis, leading to chromo-
some mis-segregation and the development of aneuploid
cells in both the brain and the periphery. The presence of
aneuploid neurons in both APP and PS-1 transgenic mice
indicates that both classes of FAD-causing mutations cause
cell cycle and chromosome mis-segregation defects in neu-
ronal precursor cells.
Expression of FAD Mutant APP Causes Chromosome
Mis-Segregation and Aneuploidy in Transfected Cells
To confirm that the aneuploidy observed in FAD-APP trans-
genic mice was caused directly by the expression of the
mutated gene, we asked whether mutant APP could also
induce aneuploidy after transient expression in mammalian
cells in culture. To assure a low background level of cell
cycle defects such as aneuploidy, we used as a transfection
recipient the hTERT-HME1 cell line, a (karyotypically stable)
primary human cell line transfected with a telomerase re-
verse transcriptase gene to confer immortality (Jiang et al.,
1999; Morales et al., 1999).
Parallel cultures of hTERT cells were transiently trans-
fected with plasmids expressing a human APP gene car-
rying both the NL-APP K595N/M596L (Swedish) and
V642I (London) mutations or the V717I APP mutation.
The empty vectors served as controls. FISH with a double-
labeled probe showed that expression of mutant APP
induced chromosome mis-segregation and the develop-
ment of aneuploidy for both chromosome 21 and 12 (Fig-
ure 3, A–C), but did not induce an increase in tetraploid
cells (Figure 3D). Together, these results show that the
aneugenic activity of mutant APP expression likely affects
all chromosomes randomly and therefore probably alters
an essential aspect of normal mitosis. Mutant APP did not
induce aborted cell cycles in which DNA replication oc-
curs without a subsequent cell division in these short-
term experiments.
AD-causing Peptides Induce Chromosome Mis-Segregation
and Aneuploidy
Because overexpression or mutation in either PS-1 or APP
cause cell cycle defects and chromosome mis-segregation, we
hypothesized that the product of APP cleavage by PS-1—the
A peptide itself—might be the effector molecule responsible
for disrupting the mitotic spindle (Boeras et al., 2008). We tested
Figure 2. Trisomy 16 induced in neurons of mice
carrying a mutant APP transgene. Quantitative FISH
analysis of resuspended cells from the whole brain
of FAD mutant V717F mice costained with the NeuN
antibody (A) revealed significantly higher levels of
trisomy 16 compared with nontransgenic animals.
Most of the aneuploidy was due to trisomy 16 neu-
rons (B and C). No significant increase in tetrasomy
16 was detected (D).
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this hypothesis by directly exposing cells in culture to A and
various control peptides for 48 h and counting chromosomes
by karyotype analysis and by FISH. Both A1-40 and A1-42
induced significant chromosome mis-segregation and an-
euploidy in cultured hTERT cells within 48 h whereas the
A 42-1 reverse peptide, the A1-42 scrambled peptide and
the A12-28 scrambled peptide had no significant effect on
untreated cells (Figure 4A,B), a result confirmed by FISH anal-
ysis of chromosomes 21 and 12 (Figure 5, A–C).
Mechanism of A-induced Chromosome Mis-Segregation:
Roles for Tau and APP
To investigate the mechanism by which A, and by im-
plication mutant APP and PS, cause cells to undergo
chromosome mis-segregation and yield aneuploid daugh-
ters, we assumed that its aneugenic function was related
to the peptide’s other toxic activities, especially those
related to MT-based transport, which is, of course, re-
quired for proper chromosome segregation. The data of
Figure 6, A and B, show that pretreating normal spleno-
cytes with BAPTA, which chelates extracellular Ca2 and
thus inhibits, for instance, calpain activation, or with LiCl,
which inhibits GSK-3, prevents A from inducing chro-
mosome mis-segregation. BAPTA and LiCl have previ-
ously been shown to inhibit A toxicity (Lee et al., 2000;
Takashima 2006).
Numerous studies, both in vitro and in vivo, have
shown that A (and FAD mutant PS-1 and APP) induces
increased phosphorylation of the MT-associated protein
Tau, the main component of the intraneuronal paired
helical filaments and neurofibrillary tangles of AD (Lee
1996; Pigino et al., 2001; Small and Duff, 2008). Indeed, the
toxicity of A depends on the presence of Tau (Rapoport
et al., 2002; Roberson et al., 2007). Interestingly, activated
calpain cleaves Tau, inactivating it, and yielding a toxic
fragment, and GSK-3 phosphorylates Tau at AD-PHF-
relevant sites and is itself involved in chromosome segre-
gation (Lee 1996; Wakefield et al., 2003; Park and Ferreira,
2005). We therefore investigated the role of Tau in chro-
mosome segregation. Spenocytes were prepared from
normal, Tau/, and full Tau/ knockout mice, allowed
to grow for 48 h in the presence and absence of A, and
analyzed for chromosome aneuploidy. As shown in Fig-
ure 7, A and B, knocking out one, or even more effective,
both copies of Tau led to increased aneuploidy. Addition
of A only induced a clear increase in chromosome mis-
segregation in normal cells, indicating that the aneugenic
effect of A requires and disrupts normal, Tau-stabilized,
MT function.
Figure 3. Chromosome aneuploidy induced
in cells expressing either NL-APP K595N/
M596L and V642I or V717F mutant APP.
hTERT cells were transfected with expression
vectors for the mutant human APP genes
with the empty vectors pcDNA3 or pAG3
serving as control. The transfected cells were
analyzed 48 h later. Expression of APP caused
many cells to become aneuploid, as indicated
by trisomy 21 and trisomy 12 (A–C). APP
expression failed to induce a significant in-
crease in tetrasomy for chromosome 16 (D).
Figure 4. High levels of total aneuploidy induced in hTERT cells
by either A40 or A42. In the series of seven experiments, meta-
phase karyotypes of peptide-treated hTERT cells were examined
after 48 h exposure to A and control peptides (A). Significant levels
of aneuploidy were induced by 1 M A40 and A42 compared
with A12-18-Scrambled peptide and A42-1 reverse peptide (B).
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Finally, A-induced cellular toxicity has been shown to
require the presence of full-length APP as a receptor on
the surface of the target cell, perhaps to aid in the uptake
of exogenous A or to undergo induced endocytosis and
processing to generate intracellular A (Lorenzo et al.,
2000; Shaked et al., 2006; Sola Vigo et al., 2009). We have
tested whether the effect of A on chromosome segrega-
tion in treated cells similarly requires interaction with
endogenous APP. Addition of A 40 or 42 to APP/
spleen cells fails to induce chromosome mis-segregation
and aneuploidy over background, (Figure 8). This result
further indicates that A-induced chromosome mis-seg-
regation is part of, and likely contributes to, the peptide’s
toxic action.
DISCUSSION
The preponderance of the data—from pathology, from
genetics, from biochemistry, from cell biology, and from
the mouse models designed to mimic the human dis-
ease—point to the A peptide as playing a central role in
the pathogenic pathway to AD (Hardy and Selkoe, 2002).
For example, mutations in APP or PS affect either the
sequence of A, or the cleavage of the APP protein, so as
to generate forms of A that, under the essential catalytic
influence of inflammatory proteins, specifically apoli-
poprotein E and antichymotrypsin, are more prone to first
oligomerize and then polymerize and aggregate into the
toxic amyloid deposits of AD (Wolfe, 2003; Potter et al.,
2001). Both in vitro and in vivo studies have shown that
oligomerized and/or polymerized A is toxic to neurons
(Yankner et al., 1989; Ma et al., 1994, 1996; Wisniewski
et al., 1994; Kayed et al., 2003; Chromy et al., 2003; Townsend
et al., 2006).
The importance of A is also supported by the fact that DS
patients, whose cells carry three copies of chromosome 21
(and of the APP gene) in all of their cells due to chromosome
mis-segregation during meiosis produce increased levels of
A peptide and invariably develop AD pathology at an
early age (Olson and Shaw 1969; Epstein, 1990, Potter, 1991,
2008). Even mosaic DS individuals, with only a small pro-
portion of trisomy 21 cells, develop early dementia. Further-
more, FAD can be caused by a duplication of one APP gene
on one chromosome, confirming that a mere 50% overpro-
duction of APP/A is sufficient to cause very early AD in
the context of an otherwise normal human brain (Sleegers et
al., 2006; Rovelet-Lecrux et al., 2006).
The data of this article, together with our earlier results,
support the hypothesis that a potentially important step in
the pathogenic pathway by which A overproduction leads
Figure 5. Specific chromosome aneuploidy, including trisomy
21 and trisomy 12 induced by exposure of hTERT cells to A
peptide. Quantitative FISH analysis with a dual color probe
detecting both chromosome 21 (SpectrumOrange) and 12 (Spec-
trumGreen) revealed induction of trisomy 21 and 12 (A–C), but
no significant increase of either tetrasomy 21 or 12 (data not
shown). Comparing these results with the data of Figure 3 indi-
cates that A peptides exert a general disruptive effect on chro-
mosome segregation during mitosis that includes but is not re-
stricted to chromosome 21.
Figure 6. Pretreating normal splenocytes for 3 min with 1 mM
BAPTA, a chelator of extracellular Ca2, showed a reduction in A
1-42–induced trisomy 16 (A). Similarly, the coincubation with 1 M
of A 1-42 for 48 h and 2.5 mM of LiCl, a GSK-3 inhibitor, for the
last 7 h decreased trisomy 16 (B).
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to AD is A’s interference with the cytoskeleton, leading to
chromosome mis-segregation during mitosis (Potter, 1991,
2008; see also Rassoulzadegan et al., 1998). More specifically,
the A product of the PS -secretase enzyme acting on APP,
at least in part by inactivating Tau, may contribute to AD by
inducing the mis-segregation of chromosomes and the de-
velopment of aneuploid, including trisomy 21, cells. Knock-
ing out the Tau gene also causes chromosome mis-segrega-
tion and aneuploidy.
The mechanism by which A induces cell cycle abnormal-
ities evidently involves activation of GSK-3 and the influx
of Ca2, because blocking either of these two activities re-
stores chromosome segregation to normal. In addition, Tau-
stabilized MTs are a necessary substrate for the aneugenic
activity of A. These findings are linked, for Ca2 is neces-
sary for the A-induced cleavage and inactivation of Tau
and GSK-3 for A-induced phosphorylation and inactiva-
tion of Tau and both for A toxicity (Park and Ferreira, 2005;
Takashima, 2006). Ca2 is also necessary for activation of
kinesin-like MT motors through Ca2-binding regulatory
proteins (Vinogradova et al., 2009; Wang and Schwartz,
2009). Indeed we consider it likely that A directly damages
the MT system such that Tau disconnects from MTs, be-
comes prone to cleavage, and phosphorylation, further de-
stabilizing MTs.
A’s ability to inhibit MT function and cause chromosome
mis-segregation will have major deleterious effects, particu-
larly on neurons and on their precursors. Because neurogen-
esis occurs throughout life, especially following neuronal
loss (Zhao et al., 2008), A-induced chromosome mis-segre-
gation will yield aneuploid, defective, neuronal precursor
cells and should thus inhibit the production of fully func-
tional replacement neurons, as found in FAD-tg mice and
AD patients. For instance the trisomy 21 cells that accumu-
late in AD patients overexpress APP and A, which imbal-
ance should promote the disease as it does in mosaic trisomy
21 or APP-duplication individuals who are born normal but
later develop early AD pathology and dementia. Indeed,
trisomy 21 neurons are prone to apoptosis, PS-1 mutation or
overexpression (and thus increased A production) induces
cell cycle defects in cultured cells, and mice harboring an
FAD mutant human APP or PS-1 gene have reduced neu-
rogenesis and other cell cycle defects (Wolozin et al., 1996;
Busciglio and Yankner, 1997; Janicki and Monteiro, 1999;
Chui et al., 1999; Feng et al., 2001; Wen et al., 2004; Wang
et al., 2004; Chevallier et al., 2005; Boeras et al., 2008; Zhang
et al., 2007;Verret et al., 2007; Boeras et al., 2008; Varvel et
al., 2008). Any dividing precursor or mature cell, in cul-
ture or in vivo, which cannot undergo proper chromo-
some segregation will produce defective progeny prone to
apoptosis.
A damage to MT function will also lead to intracellular
trafficking defects that will particularly affect mature neu-
rons (see for example Stokin et al., 2005; Lazarov et al.,
2007). Motor proteins needed for proper interaction of
MTs with kinetochores or other cargo require Ca2, and
stability of MTs in neurons is reduced by Ca2-dependent
cleavage of Tau or by GSK-3-dependent phosphoryla-
tion of Tau, both of which are induced by A, as discussed
above.
A direct connection between P-Tau and chromosome
mis-segregation is reinforced by the recent finding that
the P301L mutation in Tau that causes frontal temporal
dementia (FTD) also causes Tau hyperphosphorylation,
chromosome mis-segregation, and aneuploidy (Rossi et
al., 2008). Just as we showed for AD, the finding of FTD-
related chromosome defects confirms the presence of Tau,
MT disfunction, and chromosome mis-segregation on the
causal path to neurodegeneration in these two related
disorders. Interestingly, Pin1, which modulates Tau phos-
phorylation, also causes chromosome mis-segregation,
aneuploidy, and oncogenic transformation in transfected
cells (Suizu et al., 2006).
Figure 7. Knocking out Tau replicates/replaces ability of A to
induce chromosome mis-segregation. Spleen cells from normal
(WT) and Tau/ and Tau/ mice were cultured  A1-42 and
A1-40 for 48 h, and the resulting chromosome aneuploidy was
assessed (A and B). Tau/ and / cells displayed a higher-
than-normal inherent level of aneuploidy, consistent with the
requirement for Tau in the MT function in the mitotic spindle.
A’s ability to induce chromosome mis-segregation was greatly
attenuated (i.e., replaced) in Tau/ and Tau/ cells.
Figure 8. Knocking out APP in the target cells prevents A from
inducing further chromosome mis-segregation and aneuploidy.
Spleen cells from APP/ mice were cultured  A1-42, A1-40,
and scrambled A1-42 for 48 h, and the resulting chromosome 16
aneuploidy was assessed. A induced aneuploidy in the normal
(NON) cells (p  0.01), but failed (p  0.4) to increase aneuploidy
over background in the APPKO cells. Interestingly, like the
Tau/ cells examined in Figure 7, APP/ cells also exhibited
higher levels of aneuploidy compared with nontransgenic cells
(p  0.05).
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The fact that both AD and FTD are associated with ad-
vancing age and that aging leads to increased aneuploidy
even in normal neuronal precursors and other cells (Geller
and Potter, 1999; Rehen et al., 2001; Thomas and Fenech,
2008; Granic and Potter, unpublished data), further supports
the hypothesis that slow development of such aneuploidy
contributes to age-related neurodegenerative disease (Pot-
ter, 1991; Li et al., 1997). Indeed two other common age-
promoted diseases, cancer and cardiovascular disease, are
also characterized and likely promoted by chromosome
mis-segregation and aneuploidy (Duesberg, 1999; Potter
et al., 2008).
In sum, the data of this article and previous results
show that the A peptide found at increased levels in both
sporadic and familial AD interferes with mitosis and chro-
mosome segregation, thus leading to trisomy 21 mosa-
icism and other chromosome aneuploidy. The implication
of the results is that MT disruption leading to cell cycle,
chromosome mis-segregation, and other cytoskeletal de-
fects in neuronal precursor cells may underlie many of the
neurotoxic aspects of AD. The findings also suggests that
novel approaches to diagnosis and treatment directed at
detecting and preventing disruption of MT function
and/or the development of chromosome aneuploidy with
age may be successful against AD and possibly other
age-associated disorders.
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